Global warming can result in the rise of Sea Level (SL) by 40–100 cm by the end of the XXI century with possible catastrophic consequences for coastal zone. Study and prediction of long-term fluctuations of sea level is among the most important problems of modern hydrometeorology. A series of studies of SL interannual fluctuations have been carried out in RSHU. A reconstruction of SL fluctuations during the observation period of 1861-2010, i.e. 150 years, was performed on the basis of the developed statistical model showing a powerful linear trend describing 94% of the initial row dispersion. During the XX century the trend approached 1.8 mm/year. The comparison of actual and calculated SL trends for two periods (1980–2005 and 1993-2003) has shown that the residual error makes respectively 0.21 and 0.22 mm/year that is three times less, than in the Fourth IPCC report. Also, for the first time the complex of methods of SL longterm forecast was developed: the main advantage of a simple statistical model of SL longterm forecast is a minimum of initial information, but the model accuracy is comparable with complex and expensive ocean and atmosphere circulation models. The two-decade range physical-statistical sea level prediction model was developed for the first time based on the idea that Global Air Temperature (GAT) is a major factor of SL changes. It was experimentally shown that there is a long delay (20 and 30 years) of SL fluctuations with respect to Global Air Temperature.

В статье приводятся результаты анализа экономической эффективности ФЦП, наиболее значимых для Минобрнауки РФ.

Dr. Susekov received grants from Sanofi-Aventis, Novartis, KRKA, Gedeon-Richter, Amgen, ISIS Pharmaceuticals, C5 Reseach, and Merck. He is a lecturer for AstraZeneca, Pfizer, KRKA, Gedeon-Richter, Abbott, TEVA Pharmaceuticals, Amgen, and Sanofi/Regeneron.

Hypercholesterolemia is a proven risk factor for atherosclerotic cardiovascular diseases and for their complications. Aim. To assess the quality of diagnosis and treatment of patients with severe hypercholesterolemia (total cholesterol >6.2 mmol/L) in the real outpatient practice. Material and methods. All patients with a diagnosis of arterial hypertension, ischemic heart disease, chronic heart failure, atrial fibrillation applied to primary care physicians or cardiologists in one of the randomly selected out-patient clinic of Ryazan in March-May 2012 and included into the RECVASA registry were enrolled into the study group (n=1642). Results. The group of patients with severe hypercholesterolemia consisted of 561 (44%) patients at the age of 67 (59-75) years [Me (25% -75%)]. At that, diagnosis of hyperlipidemia was indicated only in 9% of outpatient cards. Data of one or more blood chemistries including low density cholesterol (LDC) levels were presented only in 7% of outpatient cards. 83.7% of patients with severe hypercholesterolemia were classified as patients at high or very high cardiovascular risk, but statins were recommended only to 17.8% of them. Statins were mainly recommended in moderate doses; only one patient took atorvastatin 40 mg per day. Blood LDC levels were examined only in 5% of patients during statins therapy; nobody of them reached target LDC levels. Conclusion. The study data revealed the presence of a high prevalence of severe hypercholesterolemia in patients with cardiovascular diseases and poor quality of diagnosis and treatment in these patients in the real outpatient practice.

Aim. To study what cardiac drugs currently have any comments on biomarkers and what information can be obtained by pharmacogenetic testing using data exome sequencing in patients with cardiac diseases. Material and methods. Exome sequencing in random participant of the ATEROGEN IVANOVO study and bioinformatics analysis of the data were performed. Point mutations were annotated using ANNOVAR program, as well as comparison with a number of specialized databases was done on the basis of user protocols. Results. 11 cardiac drugs and 7 genes which variants can influence cardiac drug metabolism were analyzed. According to exome sequencing of the participant we did not reveal allelic variants that require dose regime correction and careful efficacy control. Conclusion. The exome sequencing application is the next step to a wide range of personalized therapy. Future opportunities for improvement of the risk-benefit ratio in each patient are the main purpose of the collection and analysis of pharmacogenetic data.

Clinical case study is described. Patient D, 55 years old, applied to the Lipid clinic of State Research Centre for Preventive Medicine because of low blood cholesterol level. Results of the differential diagnosis of the hypocholesterolemia syndrome by using exomic sequencing are presented. This method allows to sequence the majority of regions of genome containing exons, protein-coding parts of genes. Heterozygous mutation in the gene for APOB (5 nucleotides deletion) was found out in the patient by using exomic sequencing. This mutation leads to a premature stop codon with violation of apolipoprotein B-100 synthesis and causes inherited monogenic disease family hypobetalipoproteinemia.